Gunderson Capital Management Inc. Makes New Investment in Brainstorm Cell Therapeutics Inc. $BCLI

Gunderson Capital Management Inc. acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 25,950 shares of the biotechnology company’s stock, valued at approximately $29,000. Gunderson Capital Management Inc. owned approximately 0.26% of Brainstorm Cell Therapeutics at the end of the most recent quarter.

Separately, Armistice Capital LLC acquired a new stake in shares of Brainstorm Cell Therapeutics in the first quarter valued at $870,000. 14.33% of the stock is currently owned by institutional investors.

Brainstorm Cell Therapeutics Stock Down 1.4%

Shares of BCLI stock opened at $0.72 on Friday. The stock has a market capitalization of $7.95 million, a PE ratio of -0.21 and a beta of 0.30. Brainstorm Cell Therapeutics Inc. has a 52-week low of $0.52 and a 52-week high of $2.68. The stock’s 50-day moving average price is $0.69 and its 200 day moving average price is $0.95.

Analyst Upgrades and Downgrades

BCLI has been the subject of a number of recent research reports. Wall Street Zen upgraded Brainstorm Cell Therapeutics to a “sell” rating in a report on Saturday, June 14th. Maxim Group lowered Brainstorm Cell Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Brainstorm Cell Therapeutics has a consensus rating of “Hold”.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.